← All trials
NCT02473341
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2017
- Primary completion
- Jul 1, 2019
- Completion date
- Sep 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Dayanand Medical CollegeLead sponsor
- Rajasthan University of Health SciencesOverall official - principal investigator
- Institute of Liver and Biliary Sciences, IndiaOverall official - principal investigator
- Dayanand Medical CollegeReponsible party - principal investigator
- Dayanand Medical CollegeOverall official - principal investigator
- Postgraduate Institute of Medical Education and ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.